N. Giri

M. Ahn, Keunchil Park, Dong-Wan Kim, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I open‐label study to investigate the potential drug–drug interaction between single‐dose dacomitinib and steady‐state paroxetine in healthy volunteers

R. Labadie, G. Ni, N. Richie, 2014, Journal of clinical pharmacology.

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Kelvin K. W. Chan, L. Siu, Siddharth Singh, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of dacomitinib , an oral pan-human EGF receptor ( HER ) inhibitor , as fi rst-line treatment in recurrent and / or metastatic squamous-cell carcinoma of the head and neck †

A. Razak, L. Siu, S. Chia, 2013 .

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

J. Chan, R. Auchus, M. Vogiatzi, 2021, Journal of Clinical Endocrinology and Metabolism.

EGFR status and daily dose: Effect on tumor growth inhibition in cancer patients treated with dacomitinib (PF-00299804).

P. Jänne, Keunchil Park, N. Yamamoto, 2012 .

Evaluation of the Use of Static and Dynamic Models to Predict Drug-Drug Interaction and Its Associated Variability: Impact on Drug Discovery and Early Development

Hugues Dolgos, Sheila Annie Peters, P. Schroeder, 2012, Drug Metabolism and Disposition.

Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.

M. Lacouture, A. Jatoi, S. Sonis, 2015 .

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

M. Lacouture, Dong-Wan Kim, B. Cho, 2017, Lung cancer.

Abstract CT208: Absolute bioavailability of dacomitinib (PF-00299804): Comparison of oral and intravenous administration in healthy volunteers

R. Labadie, Yali Liang, N. Giri, 2014 .

Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.

J. Masters, Yali Liang, G. Ni, 2013 .

Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse

T. Terasaki, N. Shaik, Guoyu Pan, 2008, Drug Metabolism and Disposition.

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

M. Lacouture, A. Jatoi, S. Sonis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

M. Hidalgo, A. Tolcher, J. Soria, 2016, Clinical Cancer Research.

Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers

R. Labadie, N. Shaik, Yali Liang, 2017, Cancer Chemotherapy and Pharmacology.

OR25-03 The Effects of Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients with Classic Congenital Adrenal Hyperplasia: Results from A Multiple-Dose Phase 2 Study

R. Auchus, M. Vogiatzi, P. Fechner, 2020, Journal of the Endocrine Society.